LS Investment Advisors LLC Has $8.71 Million Stake in Gilead Sciences, Inc. (GILD)
LS Investment Advisors LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 122,924 shares of the biopharmaceutical company’s stock after selling 8,015 shares during the period. LS Investment Advisors LLC’s holdings in Gilead Sciences were worth $8,708,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in GILD. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Gilead Sciences by 6.5% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 109,433 shares of the biopharmaceutical company’s stock worth $7,839,000 after purchasing an additional 6,718 shares in the last quarter. Sigma Planning Corp raised its stake in shares of Gilead Sciences by 10.9% during the 4th quarter. Sigma Planning Corp now owns 30,641 shares of the biopharmaceutical company’s stock worth $2,195,000 after purchasing an additional 3,010 shares in the last quarter. Wealthstreet Investment Advisors LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $5,151,000. Accident Compensation Corp raised its stake in shares of Gilead Sciences by 3.2% during the 4th quarter. Accident Compensation Corp now owns 64,097 shares of the biopharmaceutical company’s stock worth $4,592,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Buckley Wealth Management LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $2,144,000. Institutional investors own 77.64% of the company’s stock.
GILD opened at $77.37 on Friday. Gilead Sciences, Inc. has a 1-year low of $64.27 and a 1-year high of $89.54. The company has a current ratio of 2.84, a quick ratio of 2.75 and a debt-to-equity ratio of 1.32. The firm has a market capitalization of $100.60 billion, a P/E ratio of 10.04, a price-to-earnings-growth ratio of -6.72 and a beta of 1.12.
The firm also recently declared a quarterly dividend, which was paid on Thursday, June 28th. Investors of record on Friday, June 15th were paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date of this dividend was Thursday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.
In other Gilead Sciences news, Director John Francis Cogan sold 5,833 shares of the company’s stock in a transaction on Friday, April 27th. The stock was sold at an average price of $73.91, for a total value of $431,117.03. Following the transaction, the director now directly owns 58,452 shares of the company’s stock, valued at approximately $4,320,187.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction on Friday, June 1st. The shares were sold at an average price of $68.13, for a total value of $3,406,500.00. Following the completion of the transaction, the director now directly owns 3,067,762 shares in the company, valued at $209,006,625.06. The disclosure for this sale can be found here. In the last 90 days, insiders sold 161,669 shares of company stock worth $11,367,482. 1.30% of the stock is owned by company insiders.
A number of brokerages have recently issued reports on GILD. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research note on Wednesday. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, July 10th. Credit Suisse Group set a $80.00 price objective on Gilead Sciences and gave the stock a “hold” rating in a research note on Tuesday, April 17th. Morgan Stanley dropped their price objective on Gilead Sciences from $85.00 to $81.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 2nd. Finally, Barclays dropped their price objective on Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 2nd. Eleven analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $88.26.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
See Also: Book Value Per Share in Stock Trading
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.